Sanofi and GSK announced on May 27 the start of a phase 3 clinical trial for their COVID-19 recombinant vaccine candidate which, in phase 2 initial results shared May 17, demonstrated strong immune responses across all adult age groups.
Our adjuvanted recombinant protein-based vaccine candidate
The vaccine antigen is the spike protein that will stimulate the immune system to produce antibodies against the virus
Our mRNA-based vaccine candidate
The antigen is produced in the body’s cells using the genetic coding for the spike protein against which the immune system will respond by producing antibodies against the virus
Sanofi’s Commitment to Fighting COVID-19
Throughout the ongoing pandemic, Sanofi has joined forces to fight COVID-19